双向电泳联合MALDI-TOF-MS技术在筛选食管癌铂类耐药患者中的应用研究  

Application Study of Two-Dimensional Electrophoresis Combined with MALDI-TOF-MS in Screening of Platinum Resistance in Patients with Esophageal Carcinoma

作　　者：马俊[1] 缪蓉[2] 鲁建军[1] 顾勇[1] 巫国勇[1] 罗红鹤[1] 钟佛添[1] 

机构地区：[1]中山大学附属第一医院胸外科,广东广州510080 [2]中山大学附属第一医院手术室,广东广州510080

出　　处：《现代生物医学进展》2015年第31期6107-6111,共5页Progress in Modern Biomedicine

基　　金：广东省科技计划资助项目(2011B031800117)

摘　　要：目的:采用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)技术检测食管癌(EC)患者化疗敏感性血清蛋白质谱,指导临床EC患者化疗方案的选择。方法:收集2013年1月至2014年6月我院收治的EC术后复发并行含铂化疗的患者40例,按照化疗疗效分为敏感组和耐药组。将两组蛋白质双向凝胶电泳图谱用Image Master 2D platinum 5.0软件分析并匹配,筛选出两组差异斑点,并采用MALDI-TOF-MS技术检测EC患者化疗敏感性血清蛋白质谱。结果:两组差异斑点共有68个,以耐药组为参照,敏感组患者血清蛋白下调的斑点有42个,上调的斑点有26个。从这68个差异斑点中筛选出8个斑点进行质谱鉴定,通过数据库检索分析和鉴定最终确定上述斑点所对应的蛋白质名称分别为Kininogen-1,Alpha-2-HS-glycoprotein,Fibrinogen beta chain,Clusterin,Retinol-binding protein 4,Beta-2-glycoprotein 1,Ig kappa chain C region,Complement C4-A。结论:基于铂类化疗的EC敏感患者和耐药患者间存在差异表达蛋白。Objective： To detect the chemosensitivity serum protein profiling by matrix-assisted laser desorption/ionization time of flight mass spectrometry（MALDI-TOF-TOF-MS） in patients with esophageal carcinoma（EC）, in order to guide the choice of chemotherapy regimen for clinical CE patients. Methods： Selected 40 patients with CE who were postoperative recurrence and continued with platinum chemotherapy in our hospital from January 2013 to June 2014, they were divided into sensitive group and resistant group according to the chemotherapy effect. Then analyzed and matched the protein two-dimensional gel electrophoresis of two groups by the software of Image Master 2D platinum 5.0, screened their differential spots, and detected the chemosensitivity serum protein profiling by MALDI-TOF-TOF-MS in patients with EC. Results： There were a total of 68 differential spots in two groups,took the resistant group as the reference, there were 42 spots with down-regulated serum protein, and 26 spots with up-regulated serum proteins in sensitive group.Selected 8 spots from above 68 differential spots to implemented the mass spectrometry identification, the results were analyzed and confirmed by the database,named as Kininogen-1,Alpha-2-HS-glycoprotein,Fibrinogen beta chain, Clusterin, Retinol-binding protein 4,Beta-2-glycoprotein 1, Ig kappa chain C region, Complement C4-A. Conclusion： There are protein expression difference between sensitive and resistant patients with EC with platinum chemotherapy.

关 键 词：MALDI-TOF-MS 化疗耐药 食管癌 蛋白质谱 

分 类 号：R735.1[医药卫生—肿瘤]